EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

COVID-19 Variants and Vaccine Development

Ziyao Zhao, Sahra Bashiri iD, Zyta M Ziora iD, Istvan Toth, Mariusz Skwarczynski iD

Viruses · 2024

DOI: 10.3390/v16050757 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Ziyao Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, COVID-19, Vaccine Development. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and fatalities worldwide. Extensive SARS-CoV-2 research has been conducted to develop therapeutic drugs and prophylactic vaccines, and even though some drugs have been approved to treat SARS-CoV-2 infection, treatment efficacy remains limited. Therefore, preventive vaccination has been implemented on a global scale and represents the primary approach to combat the COVID-19 pandemic. Approved vaccines vary in composition, although vaccine design has been based on either the key viral structural (spike) protein or viral components carrying this protein. Therefore, mutations of the virus, particularly mutations in the S protein, severely compromise the effectiveness of current vaccines and the ability to control COVID-19 infection. This review begins by describing the SARS-CoV-2 viral composition, the mechanism of infection, the role of angiotensin-converting enzyme 2, the host defence responses against infection and the most common vaccine designs. Next, this review summarizes the common mutations of SARS-CoV-2 and how these mutations change viral properties, confer immune escape and influence vaccine efficacy. Finally, this review discusses global strategies that have been employed to mitigate the decreases in vaccine efficacy encountered against new variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesCOVID-19Vaccine DevelopmentMutationHumansSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2

Stichwörter der Autor:innen

COVID-19SARS-CoV-2mutationsvaccinationvaccine effectivenessvariants

Substanzen

COVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Angiotensin-Converting Enzyme 2

Autor:innen und Institutionen

  • School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
  • Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
  • School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia.

ORCID-Profile: Sahra Bashiri, Zyta M Ziora, Mariusz Skwarczynski

Förderung

  • Australian Research Council

Zitieren

APA

Zhao, Z., Bashiri, S., Ziora, Z. M., Toth, I., & Skwarczynski, M. (2024). COVID-19 Variants and Vaccine Development. Viruses. https://doi.org/10.3390/v16050757

Vancouver

Zhao Z, Bashiri S, Ziora ZM, Toth I, Skwarczynski M. COVID-19 Variants and Vaccine Development. Viruses. 2024. doi:10.3390/v16050757

BibTeX
@article{Zhao2024,
  author = {Zhao, Ziyao and Bashiri, Sahra and Ziora, Zyta M and Toth, Istvan and Skwarczynski, Mariusz},
  title = {COVID-19 Variants and Vaccine Development},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16050757}
}
Kostenlos starten →